Hypersensitivity Vasculitis Differential Diagnoses

1. Mackel SE, Jordon RE. Leukocytoclastic vasculitis. A cutaneous expression of immune complex disease. Arch Dermatol. 1982 May. 118(5):296-301. [QxMD MEDLINE Link].

2. Kevil CG, Bullard DC. Roles of leukocyte/endothelial cell adhesion molecules in the pathogenesis of vasculitis. Am J Med. 1999 Jun. 106(6):677-87. [QxMD MEDLINE Link].

3. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007 Jul. 86 (4):242-51. [QxMD MEDLINE Link].

4. Fujikawa K, Kawakami A, Hayashi T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol. 2010 Feb. 20(1):86-9. [QxMD MEDLINE Link].

5. Lowry MD, Hudson CF, Callen JP. Leukocytoclastic vasculitis caused by drug additives. J Am Acad Dermatol. 1994 May. 30(5 Pt 2):854-5. [QxMD MEDLINE Link].

6. Pendergraft WF 3rd, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol. 2014 Jan. 26(1):42-9. [QxMD MEDLINE Link].

7. Loricera J, Calvo-Rio V, Ortiz-Sanjuan F, Gonzalez-Lamuno D, Martínez-Taboada VM, González-Gay MA, et al. The spectrum of paraneoplastic cutaneous vasculitis in a: defined population. Medicine (Baltimore). 2013. 92:331.

8. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan. 65(1):1-11. [QxMD MEDLINE Link].

9. Arora A, Wetter DA, Gonzalez-Santiago TM, Davis MD, Lohse CM. Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2014 Nov. 89 (11):1515-24. [QxMD MEDLINE Link].

10. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Garcia-Fuentes M. Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore). 1998 Nov. 77(6):403-18. [QxMD MEDLINE Link].

11. Garcia-Porrua C, Gonzalez-Gay MA. Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schönlein purpura in adults. Semin Arthritis Rheum. 1999 Jun. 28(6):404-12. [QxMD MEDLINE Link].

12. Garcia-Porrua C, Gonzalez-Gay MA, Lopez-Lazaro L. Drug associated cutaneous vasculitis in adults in northwestern Spain. J Rheumatol. 1999 Sep. 26(9):1942-4. [QxMD MEDLINE Link].

13. Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM. Clinical approach to cutaneous vasculitis. Curr Opin Rheumatol. 2005 Jan. 17(1):56-61. [QxMD MEDLINE Link].

14. Gonzalez-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore). 1999 Sep. 78(5):292-308. [QxMD MEDLINE Link].

15. Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol. 2008. 9(2):71-92. [QxMD MEDLINE Link].

16. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol. 2003 Mar. 48(3):311-40. [QxMD MEDLINE Link].

17. Sams WM Jr. Hypersensitivity angiitis. J Invest Dermatol. 1989 Aug. 93(2 Suppl):78S-81S. [QxMD MEDLINE Link].

18. Zurada JM, Ward KM, Grossman ME. Henoch-Schönlein purpura associated with malignancy in adults. J Am Acad Dermatol. 2006 Nov. 55(5 Suppl):S65-70. [QxMD MEDLINE Link].

19. Solans-Laque R, Bosch-Gil JA, Perez-Bocanegra C, Selva-O'Callaghan A, Simeon-Aznar CP, Vilardell-Tarres M. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol. 2008 Feb. 35(2):294-304. [QxMD MEDLINE Link].

20. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007 Dec 15. 57(8):1473-80. [QxMD MEDLINE Link].

21. Xu LY, Esparza EM, Anadkat MJ, Crone KG, Brasington RD. Cutaneous manifestations of vasculitis. Semin Arthritis Rheum. 2009 Apr. 38(5):348-60. [QxMD MEDLINE Link].

22. Piette WW, Stone MS. A cutaneous sign of IgA-associated small dermal vessel leukocytoclastic vasculitis in adults (Henoch-Schönlein purpura). Arch Dermatol. 1989 Jan. 125(1):53-6. [QxMD MEDLINE Link].

23. Loricera J, Calvo-Río V, Mata C, Ortiz-Sanjuán F, González-López MA, Alvarez L, et al. Urticarial vasculitis in northern Spain: clinical study of 21 cases. Medicine (Baltimore). 2014 Jan. 93(1):53-60. [QxMD MEDLINE Link].

24. Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol. 2006 Jan. 45 (1):3-13. [QxMD MEDLINE Link].

25. Davis MD, Daoud MS, Kirby B, Gibson LE, Rogers RS 3rd. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol. 1998 Jun. 38(6 Pt 1):899-905. [QxMD MEDLINE Link].

26. Wisnieski JJ, Baer AN, Christensen J, et al. Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients. Medicine (Baltimore). 1995 Jan. 74(1):24-41. [QxMD MEDLINE Link].

27. Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol. 1985 Aug. 13(2 Pt 1):193-200. [QxMD MEDLINE Link].

28. Sais G, Vidaller A, Jucgla A, Gallardo F, Peyri J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol. 1995 Dec. 131(12):1399-402. [QxMD MEDLINE Link].

29. Jachiet M, Flageul B, Deroux A, et al. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol. 2015 Feb. 67 (2):527-34. [QxMD MEDLINE Link].

30. Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol. 1994. 370:411-6. [QxMD MEDLINE Link].

31. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther. 2007 Jul-Aug. 20(4):216-28. [QxMD MEDLINE Link].

32. Ong CS, Benson EM. Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol. 2000 Aug. 143 (2):447-9. [QxMD MEDLINE Link].

33. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006 Jan 15. 173(2):180-7. [QxMD MEDLINE Link]. [Full Text].

34. Chung L, Funke AA, Chakravarty EF, Callen JP, Fiorentino DF. Successful use of rituximab for cutaneous vasculitis. Arch Dermatol. 2006 Nov. 142(11):1407-10. [QxMD MEDLINE Link].

35. Harper L. Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Rheumatol. 2010 Jan. 22(1):37-42. [QxMD MEDLINE Link].

36. Lunardi C, Bambara LM, Biasi D, Zagni P, Caramaschi P, Pacor ML. Elimination diet in the treatment of selected patients with hypersensitivity vasculitis. Clin Exp Rheumatol. 1992 Mar-Apr. 10(2):131-5. [QxMD MEDLINE Link].

37. Tancrede-Bohin E, Ochonisky S, Vignon-Pennamen MD, Flageul B, Morel P, Rybojad M. Schönlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. Arch Dermatol. 1997 Apr. 133(4):438-42. [QxMD MEDLINE Link].

38. Callen JP. Cutaneous vasculitis: Relationship to systemic disease and therapy. Curr Probl Dermatol. 1993. 5:45-80.

39. Ekenstam Eaf, Callen JP. Cutaneous leukocytoclastic vasculitis. Clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol. 1984 Apr. 120(4):484-9. [QxMD MEDLINE Link].

40. Cakiter AU, Kucuk OS, Ozkaya DB, Topukcu B, Onsun N. Demographic characteristics, aetiology, and assessment of treatment options in leukocytoclastic vasculitis. Postepy Dermatol Alergol. 2017 Apr. 34 (2):104-109. [QxMD MEDLINE Link].

Ruth Ann Vleugels, MD, MPH Assistant Professor of Dermatology, Harvard Medical School; Associate Physician, Department of Dermatology, Brigham and Women's Hospital; Associate Physician, Department of Immunology and Allergy, Children's Hospital Boston

Ruth Ann Vleugels, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Rheumatology, American Medical Association, Society for Investigative Dermatology, Medical Dermatology Society, Dermatology Foundation

Disclosure: Nothing to disclose.

Camila S Villa-Ruiz, MPH MD Candidate, Ponce School of Medicine, Puerto Rico

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received income in an amount equal to or greater than $250 from: Biogen US (Adjudicator for study entry cutaneous lupus erythematosus); Priovant (Adjudicator for entry into a dermatomyositis study); IQVIA (Serono - adjudicator for a study of cutaneous LE) <br/>Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for these trust accounts for: Stocks held in various trust accounts: Allergen; Amgen; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble;; Celgene; Gilead; CVS; Walgreens; Bristol-Myers Squibb.

Michael J Wells, MD, FAAD Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Jeffrey J Miller, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Society for Investigative Dermatology, Association of Professors of Dermatology, North American Hair Research Society

Disclosure: Nothing to disclose.

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD<br/>Served as a speaker for various universities, dermatology societies, and dermatology departments.

Mital Patel-Cohen, MD Summit Medical Group

Mital Patel-Cohen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Women's Association, Dermatology Foundation, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, Medical Dermatology Society, Rheumatologic Dermatology Society, Women's Dermatologic Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Abbvie.

• Print this section
• Print the entire contents of
• Print the entire contents of article